Nasal administration of agents for the treatment of gastroparesis

a gastroparesis and agent technology, applied in the field of nasal administration, can solve the problems of affecting the treatment effect, and affecting the treatment effect, and achieving the effects of reducing the risk of bezoars, and improving the quality of li

a gastroparesis and agent technology, applied in the field of nasal administration, can solve the problems of affecting the treatment effect, and affecting the treatment effect, and achieving the effects of reducing the risk of bezoars, and improving the quality of li

US20030059374A1Inactive Publication Date: 2003-03-27LEHMAN LAURA S +6
0 Cites 16 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nasal administration of agents for the treatment of gastroparesis
  • Nasal administration of agents for the treatment of gastroparesis
  • Nasal administration of agents for the treatment of gastroparesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The invention is directed to a method for treating and controlling gastroparesis by nasally administering MCP or a pharmaceutically acceptable salt thereof. MCP is formulated to contain a therapeutically effective amount of MCP such that upon administration by the intranasal route, a therapeutically effective amount of MCP is delivered to the patient. In addition, the therapeutically effective amount of MCP, in both aqueous and non-aqueous formulations, is chosen to minimize the severity and incidence of untoward side-effects and drug-interactions encountered with MCP. Compared to the injectable form and oral form of MCP, intranasal administration of MCP has the advantage of being painless, effective, safe, and consistent, particularly for patients with gastroparesis.

[0024] 5.1 Pharmacokinetic Data: Selection of Doses in the Study

[0025] The pharmacokinetic data from three single dose, crossover pharmacokinetic studies in healthy patients was evaluated to determine appropriate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
movementaaaaaaaaaa
Login to View More

Abstract

The present invention is directed to a method for the treatment of gastroparesis by the use of metoclopramide nasal formulation.

Description

1. FIELD OF THE INVENTION[0001] The present invention is directed to a method for treating gastroparesis. More particularly, the present invention is directed to a method for treating gastroparesis typically caused by diabetes mellitus (including type 1 and type 2 diabetes), postviral syndromes, anorexia nervosa, malnutrition, alcoholism, surgery on the stomach or vagus nerve, medications, particularly anticholinergics and narcotics which slow contractions in the intestine, gastroesophageal reflux disease, smooth muscle disorders such as amyloidosis and scleroderma, nervous system diseases (including abdominal migraine and Parkinson's disease), or metabolic disorders (including hypothyroidism) with the nasal administration of metoclopramide.2. BACKGROUND OF THE INVENTION[0002] The vagus nerve controls the movement of food through the digestive tract. Normally, stomach muscles contract about three times a minute and the stomach empties within 90-120 minutes after eating. When the vag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
27 Mar 2003
Publication
US20030059374A1
IPC
A61K9/00; A61K31/16; A61K31/165; A61K31/166; A61K45/06
CPC
A61K9/0043; A61K31/16; A61K31/165; A61K31/166; A61K45/06; A61K2300/00; A61P1/00; A61P1/14
Inventors
LEHMAN, LAURA S.; TIERNEY, DAVID